Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer
Authors:
- Shinzo TakamoriSTShinzo Takamori
- Teruhiko FujiiTFTeruhiko Fujii
- Mayumi OnoMOMayumi Ono
- Hideaki YamanaHYHideaki Yamana
- Michihiko KuwanoMKMichihiko Kuwano
- Kazuo ShirouzuKSKazuo Shirouzu
- 1 December 2005
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 230 (1) , 33-46
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 33 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000
- Anticancer drug targets: growth factors and growth factor signalingJournal of Clinical Investigation, 2000
- ZD1839 (???Iressa???)*,??? as an Anticancer AgentDrugs, 2000
- Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225Oncogene, 1999
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996
- Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neuJournal of Steroid Biochemistry, 1989